Pharming Group
PHAR
16 hedge funds and large institutions have $1.31M invested in Pharming Group in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 3 closing their positions.
136% more capital inflows, than outflows
Capital inflows: $234K | Capital outflows: $99.4K
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
23% more funds holding
Funds holding: 13 → 16 (+3)
0.01% more ownership
Funds ownership: 0.12% → 0.13% (+0.01%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Crossmark Global Holdings
Houston,
Texas
|
+$180K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$25.8K |
| 3 |
Silver Grove Financial Group
Orchard Park,
New York
|
+$15.5K |
| 4 |
Optiver Holding
Amsterdam,
Netherlands
|
+$4.42K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$565 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBCM
Silverberg Bernstein Capital Management
Armonk,
New York
|
-$46.3K |
| 2 |
NewEdge Advisors
New Orleans,
Louisiana
|
-$28.4K |
| 3 |
EverSource Wealth Advisors
Birmingham,
Alabama
|
-$9.27K |
| 4 |
SmartHarvest Portfolios
Poulsbo,
Washington
|
-$5.53K |
| 5 |
Larson Financial Group
St Louis,
Missouri
|
-$4.87K |
PHAR Hedge Fund Activity: Q2 2026 in Review
16 of the 8,369 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q2 2026, worth a combined $1.31M — down 8% from $1.43M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PHAR positions and 3 closed out — a net gain of 3 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Crossmark Global Holdings, opening a new position worth an estimated $180K. The largest seller was Silverberg Bernstein Capital Management, cutting an estimated $46.3K.
- 16 institutional investors held Pharming Group (PHAR) as of Q2 2026, up from 13 in Q1 2026.
- Funds reported $1.31M of Pharming Group stock for Q2 2026, down 8% quarter-over-quarter.
- 6 funds opened new Pharming Group positions in Q2 2026 and 3 closed out, a net change of +3 holders.
- The largest Pharming Group buyer in Q2 2026 was Crossmark Global Holdings, an estimated $180K added.
- The largest Pharming Group seller in Q2 2026 was Silverberg Bernstein Capital Management, an estimated $46.3K sold.
Based on aggregated 13F filings for Q2 2026.